UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Recommendations

Info

Presentations A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. Authors*: John H. Sampson, Antonio Marcilio Padula Omuro, Matthias Preusser, Michael Lim, Nicholas A. Butowski, Timothy Francis Cloughesy, Lewis C. Strauss, Robert Raymond Latek, Prashni Paliwal, Michael Weller, David A. Reardon Abstract #: TPS2079 Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM Location: Hall A, Poster Board #265b Session: Central Nervous System Tumors Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS2079) Butowski Research Interests: My research includes translational research and a wide range of clinical trials, including those with convection-enhanced delivery (CED) with real-time MRI imaging, targeted agents, immunotherapy, and combination strategies. I am the Director of Translational Research in Neuro-Oncology and lead the translational effort on behalf of the UCSF Brain Tumor Research Center and Preclinical Core. My work has helped to create the groundwork for allied research in neuro-oncology and an extensive UCSF clinical trial portfolio for patients with primary brain and spine tumors, including an assortment of immunotherapy trials and surgically based trials. I have also designed investigator initiated trials, including a clinical trial employing intratumoral delivery with real-time MRI imaging as well as those with a range of novel targets, molecular markers and imaging biomarkers. I have also authored a number of peer-reviewed papers and presented work at national and international meetings. https://www.ucsfhealth.org/nicholas.butowski __________________________________________________________________________ Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM). Authors*: David A. Reardon, Thomas Joseph Kaley, Jorg Dietrich, Michael Lim, Gavin P Dunn, Hui Kong Gan, Timothy Francis Cloughesy, Jennifer Leigh Clarke, Andrew J. Park, Mary J. Macri, Aileen Ryan, Toni Ricciardi, Vijay Reddy, Ralph Rudolph Venhaus Abstract #: TPS2080 Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM Location: Hall A, Poster Board #266a Session: Central Nervous System Tumors Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS2080) *UCSF authors in bold 34
Presentations ATLAS: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy. Authors*: Howard M. Sandler, Michael R. McKenzie, Bertrand F. Tombal, Edwina Baskin-Bey, Stephen J. Freedland, Mack Roach, Anders Widmark, Alberto Bossi, Adam Dicker, Thomas Wiegel, Neal D. Shore, Matthew Raymond Smith, Margaret K. Yu, Thian Kheoh, Shibu Thomas, David P. Dearnaley Abstract #: TPS5087 Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM Location: Hall A, Poster Board #437a Session: Genitourinary (Prostate) Cancer Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS5087) __________________________________________________________________________ Intense exercise for survival among men with metastatic castrateresistant prostate cancer (INTERVAL – MCRPC): A Movember funded multicenter, randomized, controlled phase III study. Authors*: Fred Saad, Stacey A. Kenfield, June M. Chan, Nicolas H. Hart, Kerry S. Courneya, James Catto, Stephen P. Finn, Rosemary Greenwood, Daniel C Hughes, Lorelei A. Mucci, Stephen R Plymate, Michael N. Pollak, Stephan F.E. Praet, Aaron P. Russell, Emer M. Guinan, Erin Van Blarigan, Orla Casey, Mark Buzza, Charles J. Ryan, Robert Usher Newton Abstract #: TPS5092 Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM Location: Hall A, Poster Board #439b Poster Session: Genitourinary (Prostate) Cancer Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS5092) Ryan Research Interests: Dr. Ryan’s clinical practice focuses predominantly on advanced prostate cancer as well as germ cell (testicular) tumors and other malignancies of the genitourinary tract. His clinical and research work centers on the design and conduct of clinical trials of novel therapies for advanced prostate cancer, specifically secondary hormonal therapies targeting adrenal androgen signaling, androgen receptor targeted therapy and chemotherapy. In addition to clinical trials, Dr. Ryan collaborates with many laboratories researching the role of the androgen receptor and other signaling mechanisms in prostate cancer patients. http://cancer.ucsf.edu/people/profiles/ryan_charles.3649 *UCSF authors in bold 35
Page 1 and 2: UCSF HELEN DILLER FAMILY COMPREHENS
Page 3 and 4: HDFCCC Overview A Designated NCI Co
Page 5 and 6: HDFCCC Overview Core Capabilities S
Page 7 and 8: Presentations Presentations View fu
Page 9 and 10: Presentations Phase II trials of ce
Page 11 and 12: Presentations CRS-207 immunotherapy
Page 13 and 14: Presentations Long-term OS for pati
Page 15 and 16: Presentations Randomized phase 2 st
Page 17 and 18: Presentations Genomic Profiling to
Page 19 and 20: Presentations Validating RNAseq-sig
Page 21 and 22: Presentations Phase I/II study of V
Page 23 and 24: Presentations Clinical and genomic
Page 25 and 26: Presentations IMAAGEN trial safety
Page 27 and 28: Presentations Immunogenicity of sip
Page 29 and 30: Presentations Pembrolizumab for adv
Page 31 and 32: Presentations Novel T cell exhausti
Page 33: Presentations Correlation between m
Page 37 and 38: Presentations A prospective analysi
Page 39 and 40: Presentations Circulating Biomarker
Page 41 and 42: Presentations Extended follow-up re
Page 43 and 44: Presentations Adjuvant temozolomide
Page 45 and 46: Presentations Ribociclib (LEE011) a
Page 47 and 48: Presentations Androgen receptor (AR
Page 49 and 50: Presentations Efficacy and hematolo
Page 51 and 52: Presentations IMpassion130: a Phase
Page 53 and 54: Presentations Randomized phase II t
Page 55 and 56: Presentations Phase II trial with t
Page 57 and 58: Presentations Academic and Communit
Page 59 and 60: Presentations Prevention of everoli
Page 61 and 62: Presentations A phase 2 randomized,
Page 63 and 64: Presentations PD-L1 expression, Can
Page 65 and 66: Presentations The Heart of the Matt
Page 67 and 68: Presentations 4-year results of the
Page 69 and 70: Presentations Impact of landmark re
Page 71 and 72: Presentations Phase II study of ali
Page 73 and 74: Presentations Can lay health worker
Page 75 and 76: Presentations Medical Management of
Page 77 and 78: Presentations Prospective evaluatio
Page 79 and 80: Presentations A phase II randomized
Page 81 and 82: Presentations Early, molecular dete
Page 83 and 84: Presentations Metastatic melanoma,
Page 85 and 86:
Presentations Three-year overall su
Page 87 and 88:
Presentations Heritage: A phase III
Page 89 and 90:
Presentations Determining barriers
Page 91 and 92:
Presentations Controversies in Loca
Page 93 and 94:
Presentations A pharmacodynamic stu
Page 95 and 96:
Presentations Final results of a ph
Page 97 and 98:
Presentations Comparative performan
Page 99 and 100:
Presentations Identification of sym
show all

UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?